Genomic Valley Biotech
31.76
-1.60(-4.80%)
Market Cap₹9.71 Cr
PE Ratio333.60
IndustryHealthcare
Company Performance:
1D-4.80%
1M+19.67%
6M+34.58%
1Y-40.87%
5Y+41.16%
View Company Insightsright
More news about Genomic Valley Biotech
07Aug 25
Genomic Valley Biotech Reports Q1 FY26 Results, Announces Key Appointments
Genomic Valley Biotech Limited (GVBL) released Q1 FY26 results, showing a 31.56% decrease in revenue to Rs. 6,16,000 and an 80.67% drop in net profit to Rs. 2,46,531 compared to Q1 FY25. The company appointed M/s. SBR & Co. LLP as Secretarial Auditors for 2025-2030, Mr. Navjyoti Kumar Jha as Internal Auditor for FY 2025-26, and re-appointed Mr. Yogesh Agrawal as Chairman & Managing Director for five years from September 7, 2025.
 no imag found
Genomic Valley Biotech
31.76
-1.60
(-4.80%)
1 Year Returns:-40.87%
Industry Peers
Anthem Biosciences
775.00
(+1.75%)
Advanced Enzyme Tech
321.10
(-7.82%)
CCME Global
125.00
(0.0%)
Vivo Bio Tech
23.60
(+2.43%)